169 related articles for article (PubMed ID: 38150085)
21. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
22. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.
Li J; Sang M; Zheng Y; Meng L; Gu L; Li Z; Liu F; Wu Y; Li W; Shan B
Exp Cell Res; 2021 Dec; 409(1):112891. PubMed ID: 34688610
[TBL] [Abstract][Full Text] [Related]
23. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
24. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
Zeng RJ; Zheng CW; Gu JE; Zhang HX; Xie L; Xu LY; Li EM
Mol Oncol; 2019 Sep; 13(9):2010-2030. PubMed ID: 31314174
[TBL] [Abstract][Full Text] [Related]
25. Integrin β1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma.
Xu Z; Zou L; Ma G; Wu X; Huang F; Feng T; Li S; Lin Q; He X; Liu Z; Cao X
Am J Cancer Res; 2017; 7(3):531-542. PubMed ID: 28401009
[TBL] [Abstract][Full Text] [Related]
26. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
[TBL] [Abstract][Full Text] [Related]
27. The AEG-1-USP10-PARP1 axis confers radioresistance in esophageal squamous cell carcinoma via facilitating homologous recombination-dependent DNA damage repair.
Zhao X; Ma Y; Li J; Sun X; Sun Y; Qu F; Shi X; Xie Y; Liu S; Ma Y; Ji C; Hu W; Che S; Zhang X
Cancer Lett; 2023 Nov; 577():216440. PubMed ID: 37838281
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.
Liu H; Zhang J; Luo X; Zeng M; Xu L; Zhang Q; Liu H; Guo J; Xu L
Oncol Res; 2020 Feb; 28(1):65-73. PubMed ID: 31558183
[TBL] [Abstract][Full Text] [Related]
30. Reticulocalbin3: A Ca
Cai R; Wang P; Zhao X; Lu X; Deng R; Wang X; Hong C; Lin J
Cancer Sci; 2022 Oct; 113(10):3593-3607. PubMed ID: 35839283
[TBL] [Abstract][Full Text] [Related]
31. ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma.
Song Y; Cheng Y; Lan T; Bai Z; Liu Y; Bi Z; Alu A; Cheng D; Wei Y; Wei X
Cancer Lett; 2023 Feb; 554():216012. PubMed ID: 36470544
[TBL] [Abstract][Full Text] [Related]
32. Long non‑coding RNA BANCR promotes proliferation, invasion and migration in esophageal squamous cell carcinoma cells via the Raf/MEK/ERK signaling pathway.
Yu X; Huang M; Yang G
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880577
[TBL] [Abstract][Full Text] [Related]
33. Integrin-linked kinase affects the sensitivity of esophageal squamous cell carcinoma cells to chemotherapy with cisplatin via the Wnt/beta-catenin signaling pathway.
Xu T; Ma XL; Wei Y; Cao LY; Gao Y; Liu J; Zhang L
Bioengineered; 2022 May; 13(5):12532-12547. PubMed ID: 35587162
[TBL] [Abstract][Full Text] [Related]
34. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
35. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
Murakami T; Shoji Y; Nishi T; Chang SC; Jachimowicz RD; Hoshimoto S; Ono S; Shiloh Y; Takeuchi H; Kitagawa Y; Hoon DSB; Bustos MA
Mol Oncol; 2021 Apr; 15(4):1069-1087. PubMed ID: 33605536
[TBL] [Abstract][Full Text] [Related]
36. ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.
Wu J; Zhou Y; Wang T; Jiang C; Gao Y; Wei B
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101586. PubMed ID: 33662636
[TBL] [Abstract][Full Text] [Related]
37. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
[TBL] [Abstract][Full Text] [Related]
38. RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
Zhang Y; Du J; Duan X; Peng W; Lv L; Chen Z; Zhang Y
Life Sci; 2021 Mar; 269():119064. PubMed ID: 33460665
[TBL] [Abstract][Full Text] [Related]
39. FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma.
Zhai Y; Shan C; Zhang H; Kong P; Zhang L; Wang Y; Hu X; Cheng X
Mol Cell Biochem; 2022 Dec; 477(12):2689-2702. PubMed ID: 35606602
[TBL] [Abstract][Full Text] [Related]
40. YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma.
Wang XW; Zhao R; Yang ZY; Li T; Yang JC; Wang XL; Li XT; Zhao XR; Li XZ; Wang XX
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7703-7716. PubMed ID: 37000262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
